Roche Holding stock gains 1.8 percent before its October 22 update

Published on 10/06/2026 at 16:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roche Holding stock traded at CHF 355.20 on October 6, 2026, after opening at CHF 351.00. First-half sales fell 2 percent to CHF 30.364 billion.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding (ISIN CH1499059983) was trading at CHF 355.20 on SIX on October 6, 2026, up 1.8 percent from the session open of CHF 351.00. The move came as the company approaches its third-quarter sales update on October 22, 2026, a date Roche has published for investors.

October 22 brings the next test

According to Roche in its September 22, 2026 investor update, the group will publish third-quarter 2026 sales before the Swiss exchange opens on October 22, 2026. The presentation and question-and-answer session are scheduled for 14:00 CEST, giving investors a defined checkpoint for demand across pharmaceuticals and diagnostics.

The company also used its September 28, 2026 Pharma Day to highlight development productivity. Nova Pharma News reported on October 6, 2026 that Roche's Phase III success rate had reached more than 80 percent year to date, compared with 65 percent in 2025.

First-half sales fell in Swiss francs

Roche's first-half 2026 sales came to CHF 30.364 billion, down 2 percent from CHF 30.944 billion a year earlier, according to VCBeat. IFRS operating profit was CHF 9.671 billion, down 1 percent from CHF 10.33 billion in the prior-year period.

The figures show the tension behind the stock move: operating execution remains material, but currency effects continue to weigh on reported sales. Roche's investor page also lists 2025 core earnings per share growth of 11 percent at constant exchange rates and 39 million patients treated with its medicines in 2025.

Consensus target stays above the price

Analyst expectations remain higher than the October 6 trading level. In a September 8, 2026 overview, MarketScreener listed a Hold consensus from 5 analysts, an average target of CHF 375.34 and a spread of 3.09 percent above the reference price in that overview. The same page reported Barclays raising its target from CHF 410 to CHF 430 while retaining a Buy rating.

Stock remains below its yearly high

Roche Holding stock was trading at CHF 355.20 on SIX on October 6, 2026, with 39,349 shares changing hands at 9:28 a.m. The session high was also CHF 355.20, while the 52-week high stood at CHF 375.80 on August 26, 2026, leaving the current level 5.80 percent below that peak.